



## Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 6, 2018

DUBLIN, Ireland, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Feb. 2, 2018 of inducement restricted stock units for an aggregate of 45,910 ordinary shares to sixteen new employees.

Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.

The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).

### **About Horizon Pharma plc**

Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it's personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit [www.horizonpharma.com](http://www.horizonpharma.com). Follow [@HZNPplc](https://twitter.com/HZNPplc) on Twitter, like us on [Facebook](https://www.facebook.com/horizonpharma) or explore career opportunities on [LinkedIn](https://www.linkedin.com/company/horizonpharma).

### **Contacts:**

Tina Ventura  
Senior Vice President, Investor Relations  
[investor-relations@horizonpharma.com](mailto:investor-relations@horizonpharma.com)

Ruth Venning  
Executive Director, Investor Relations  
[investor-relations@horizonpharma.com](mailto:investor-relations@horizonpharma.com)

U.S. Media Contact:  
Geoffrey Curtis  
Senior Vice President, Corporate Affairs and Chief Communications Officer  
[media@horizonpharma.com](mailto:media@horizonpharma.com)

Ireland Media Contact:  
Ray Gordon  
Gordon MRM  
[ray@gordonmrm.ie](mailto:ray@gordonmrm.ie)

 [Primary Logo](#)

Source: Horizon Pharma plc